Phase
Condition
Cushing's Disease
Treatment
Seliciclib
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male and female patients at least 18 years old
Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH) production:
Persistent hypercortisolemia established by two consecutive 24-hour UFCassessment ≥1.5× the upper limit of normal
Normal or elevated ACTH levels
Pituitary adenoma (>1 cm) on MRI or inferior petrosal sinus sampling (IPSS)central to peripheral ACTH gradient >2 at baseline and >3 after CRH stimulation
Recurrent or persistent CD defined as pathologically confirmed resectedpituitary ACTH-secreting tumor or IPSS central to peripheral ACTH gradient >2at baseline and >3 after CRH stimulation, and 24h-UFC >ULN beyond post-surgicalweek 6
Patients on medical treatment for Cushing disease. The following washout periodsmust be completed before screening assessments are performed:
Inhibitors of steroidogenesis: metyrapone, ketoconazole: 2 weeks;Levoketoconazole: 3 weeks; osilodrostat: 6 weeks
Somatostatin receptor ligand pasireotide: short-acting, 2 weeks; long-acting, 4weeks
Progesterone receptor antagonist mifepristone: 2 weeks
Dopamine agonist cabergoline: 4 weeks
Patients treated with CYP3A or CYP2B6 strong inducers or inhibitors, includingthose listed below. Required washout time varies between drugs; minimum 5-6times the half-life of the drug.
Strong CYP3A inducers: apalutamide, carbamazepine, enzalutamide, mitotane,phenytoin, rifampin, St. John's wort
Moderate CYP3A inducers: bosentan, efavirenz, etravirine, phenobarbital,primidone
Weak CYP3A inducers: armodafinil, modafinil, rufinamide
Strong CYP2B6 inducer: carbamazepine
Moderate CYP2B6 inducers: efavirenz, rifampin
Weak CYP2B6 inducers: nevirapine, ritonavir
Strong CYP3A inhibitors: boceprevir, cobicistat, danoprevir and ritonavir,elvitegravir and ritonavir, grapefruit juice, indinavir and ritonavir,itraconazole, ketoconazole, lopinavir and ritonavir, paritaprevir andritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritonavir,saquinavir and ritonavir, telaprevir, tipranavir and ritonavir,telithromycin, troleandomycin, voriconazole, clarithromycin, idelalisib,nefazodone, nelfinavir.
Moderate CYP3A inhibitors: aprepitant, ciprofloxacin, conivaptan,crizotinib, cyclosporine, diltiazem, dronedarone, erythromycin,fluconazole, fluvoxamine, imatinib, verapamil
Strong CYP2B6 inhibitor: ticlopidine
Exclusion
Exclusion criteria:
Patients with compromised visual fields, and not stable for at least 6 months
Patients with abutment or compression of the optic chiasm on MRI and normal visualfields
Patients with Cushing's syndrome due to non-pituitary ACTH secretion
Patients with hypercortisolism secondary to adrenal tumors or nodular (primary)bilateral adrenal hyperplasia
Patients who have a known inherited syndrome as the cause for hormone over secretion (i.e., Carney Complex, McCune-Albright syndrome, Multiple endocrine neoplasia (MEN) 1
Patients with a diagnosis of glucocorticoid-remedial aldosteronism (GRA)
Patients with cyclic Cushing's syndrome defined by any measurement of UFC over theprevious 1 months within normal range
Patients with pseudo-Cushing's syndrome, i.e., non-autonomous hypercortisolism dueto overactivation of the hypothalamic-pituitary-adrenal (HPA) axis in uncontrolleddepression, anxiety, obsessive compulsive disorder, morbid obesity, alcoholism, anduncontrolled diabetes mellitus
Patients who have undergone major surgery within 1 month prior to screening
Patients with serum K+< 3.5 while on replacement treatment
Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C >8%
Patients who have clinically significant impairment in cardiovascular function orare at risk thereof, as evidenced by congestive heart failure (NYHA Class III orIV), unstable angina, sustained ventricular tachycardia, clinically significantbradycardia, high grade atrioventricular (AV) block, history of acute MI less thanone year prior to study entry
Patients with liver disease or history of liver disease such as cirrhosis, chronicactive hepatitis B and C, or chronic persistent hepatitis, or patients with abnormalalanine transferase (ALT) or aspartate aminotransferase (AST) at screening orpatients with advanced liver fibrosis (≥10 kPa) on elastography at screening
Patients with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
Patients not biochemically euthyroid
Patients who have any current or prior medical condition that can interfere with theconduct of the study or the evaluation of its results, such as
History of immunocompromise, including a positive HIV test result (ELISA andWestern blot). An HIV test will not be required, however, previous medicalhistory will be reviewed
Presence of active or suspected acute or chronic uncontrolled infection
History of, or current alcohol misuse/abuse in the 12 month period prior toscreening
Female patients who are pregnant or lactating, or are of childbearing potential andnot practicing a medically acceptable method of birth control. If a woman isparticipating in the trial then one form of contraception is sufficient (pill ordiaphragm) and the partner should use a condom. If oral contraception is used inaddition to condoms, the patient must have been practicing this method for at leasttwo months prior to screening and must agree to continue the oral contraceptivethroughout the course of the study and for 3 months after the study has ended. Malepatients who are sexually active are required to use condoms during the study andfor three months afterwards as a precautionary measure (available data do notsuggest any increased reproductive risk with the study drugs)
Patients who have participated in any clinical investigation with an investigationaldrug within 1 month prior to screening or patients who have previously been treatedwith seliciclib
Patients with any ongoing or likely to require additional concomitant medicaltreatment to treat CD
Patients who have received pituitary irradiation within the last 5 years prior tothe baseline visit
Patients who have been treated with radionuclide at any time prior to study entry
Patients with known hypersensitivity to seliciclib
Patients with a history of non-compliance to medical regimens or who are consideredpotentially unreliable or will be unable to complete the entire study
Patients with hepatitis B surface antigen (HbsAg) positivity
Patients with hepatitis C antibody (anti-HCV) positivity
Patients with prolonged QTcF on screening electrocardiogram (QTcF >450 msec)
Study Design
Study Description
Connect with a study center
Cedars-Sinai Medical Center
Los Angeles, California 90048
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.